Cytel

Are we meeting you this weekend at the ACCP Annual Meeting in Maryland? Make sure to catch up with our colleague Mike Fossler and check out the poster he and Abdulaziz Nanah have prepared for you! Hope to see you all there! Want to discover more? Visit www.cytel.com #ClinicalTrials #ACCP

Please give us your thoughts this happy Friday! 🎉 In the current market, we’re seeing a rise in open-source software, such as R, which is starting to give closed-source software a run for its money. Where do you see the future moving to? Do you see a hybrid approach? Or something completely different? 🤔 Please feel free to talk about this in the comments.

Did you know that 41% of oncology studies use a Data Monitoring Committee (DMC), compared to just 34% of non-oncology studies? Discover the critical role DMCs play in ensuring safety and success in oncology trials. Our experts will dive into best practices, key challenges, and innovative approaches for managing complex data in oncology studies. 🗓️ Date: September 20, 2023 ⏰ Time: 11 AM EDT Take advantage of this opportunity to enhance your understanding of oncology study oversight! Register here: https://bit.ly/3ZeEJYG #OncologyResearch #ClinicalTrials #DMCs #Webinar #LifeSciences

📊 SAS vs. R in Clinical Development. Which tool should you choose? In clinical research, choosing the right data analysis tool is crucial. SAS has long been the industry standard, but R is gaining traction with its flexibility and cost-efficiency. In our latest blog, Abhishek Ghalsasi explores the pros and cons of both tools, helping you determine which is the best fit for your clinical trials. Read more here: https://bit.ly/4dKJm1a #DataAnalysis #SAS #RProgramming #ClinicalTrials #Pharma #Biostatistics

Working on an ISE or ISS submission and you still have some questions? 🤔 Or do you just want to learn some best practices? 💡Then join us next week for our latest Office Hours with Angelo Tinazzi and Florence Le Maulf who will answer any pressing questions you may have! Register here: https://bit.ly/3AZk54z Make sure to also check out all other Office Hours we already have scheduled, some might peak your interest! #ISS #ISE #CDISC #ClinicalTrials

Is your single-arm trial showing promising results, but you're unsure how to demonstrate its value to payers without a direct comparator? Are you considering using an unanchored simulated treatment comparison (STC) to support your HTA submission? The methods and assumptions you choose could inadvertently introduce bias into your findings. In our latest blog, Cytel's #healtheconomics expert, Elizabeth Vinand shares a case study example to explore how to handle censoring in unanchored STCs. Read now: https://bit.ly/3AQQIS7 #HTA #UnanchoredSTC #SimulatedTreatmentComparison #PharmaResearch #RealWorldEvidence #HEOR #DrugDevelopment

This time, we’re asking for your opinion on our Friday poll! 🤔 We’re diving deeper into oncology trials and the main challenges we hear people face. If you’re facing challenges other than those listed, please add them in the comments so we can discuss them. 👇

🌟 Exciting Leadership Announcement 🌟 Cytel welcomes Nathalie Horowicz-Mehler, PhD as our new Global Head of Value in the Evidence, Value, and Access business! Nathalie brings over 25 years of experience in health economics and real-world evidence. She has held leadership roles at IQVIA, Concert AI, and Exponent and has a proven track record of driving growth by leading teams of scientist entrepreneurs. Nathalie has applied her clinical expertise as an epidemiologist and experience with HEOR, RWE/RWD, and advanced analytics to catalyze innovations in public health. Nathalie is a perfect fit for our team. We are excited to have her onboard and look forward to her impactful leadership! Discover more: https://hubs.ly/Q02N7s420 #Leadership #HEOR #Cytel #HealthEconomics #ComparativeEffectiveness

On the back of our great webinar on Project Optimus, our colleague Mike Fossler got invited to contribute to a piece on Project Optimus in the The Wall Street Journal! Over the past two decades, drugmakers shifted to focus on treatments such as molecularly targeted medicines aimed at proteins overabundant in tumor cells, or molecules these cells overly depend on. "Because these medicines work differently, the maximum-tolerated dose can cause significant side effects without treating tumors more effectively", said Michael Fossler, executive consultant and vice president with Cytel. éIf you give anything in a high enough dose you will get toxic off-target effects,” Fossler added. Read the full article: https://lnkd.in/eMmnfPKW

🔬 Robert Szulkin, Research Principal at Cytel, coauthored a recent publication in The Lancet Oncology that explores omitting axillary dissection as a diagnostic method in patients with luminal breast cancer. To gain a deeper understanding of the study's insights, check out the interview where Robert and coauthor Jana De Boniface discuss their findings and the broader impact on oncology research. Read the full interview here: https://hubs.ly/Q02N0Djl0 #OncologyResearch #BreastCancer #TheLancetOncology #Cytel #ClinicalTrials